A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Of The Safety And Efficacy Of PF-03654746 In Adults With Tourette's Syndrome.
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2012
At a glance
- Drugs PF 3654746 (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- 31 Jul 2012 Actual end date (11 Apr 2012) added as reported by ClinicalTrials.gov.
- 03 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 May 2012 Actual initiation date changed from Mar 2012 to Apr 2012 as reported by ClinicalTrials.gov.